Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10520
Title: Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review
Authors: Ozola Zalite, I.
Zykus, R.
Francisco Gonzalez, M.
Saygili, F.
Pukitis, A.
Gaujoux, S.
Charnley, R.M.
Keywords: Cachexia
Malnutrition
Pancreatic adenocarcinoma
Pancreatic neoplasm
Sarcopenia
Survival
Article
body mass
cachexia
cancer patient
cancer survival
Cochrane Library
consensus
disease association
human
medical literature
Medline
obesity
pancreas adenocarcinoma
priority journal
sarcopenia
systematic review
weight reduction
complication
mortality
pancreas carcinoma
pancreas tumor
prevalence
prognosis
survival rate
Carcinoma, Pancreatic Ductal
Humans
Pancreatic Neoplasms
Prevalence
Prognosis
Survival Rate
Weight Loss
Publisher: Elsevier B.V.
Abstract: Background/objectives Cachexia affects ~80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database until December 2013. After identifying relevant titles, abstracts were read and eligible articles data retrieved on preformatted sheets. The prevalence and impact of sarcopenia/cachexia on survival was evaluated. Results In total 1145 articles were retrieved, only 10 were eligible. Definitions of cachexia and sarcopenia were heterogeneous. In patients with normal weight (BMI 18.5-24.9 kg/m2) the prevalence of sarcopenia ranged from 29.7 to 65%. In overweight or obese patients (BMI >25 kg/m2) were 16.2%-67%. Sarcopenia alone was not demonstrated to be an independent factor of decreased survival, although obese sarcopenic patients were shown to have significantly worse survival in two studies. Conclusions Impact of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma is currently understudied in the available literature. Definitive association between cachexia and survival cannot be drawn from available studies, although weight loss and sarcopenic obesity might be considered as poor prognostic factors. Further prospective trials utilizing the consensus definition of cachexia and including other confounding factors are needed to investigate the impact of cachexia and sarcopenia on survival in pancreatic adenocarcinoma. © 2014 IAP and EPC.
URI: https://hdl.handle.net/11499/10520
https://doi.org/10.1016/j.pan.2014.11.006
ISSN: 1424-3903
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

141
checked on Nov 23, 2024

WEB OF SCIENCETM
Citations

133
checked on Nov 21, 2024

Page view(s)

26
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.